Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascul...
| 發表在: | Cardiology Journal |
|---|---|
| Main Authors: | , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Via Medica
2022-07-01
|
| 主題: | |
| 在線閱讀: | https://journals.viamedica.pl/cardiology_journal/article/view/75703 |